{"name":"Tarsus Pharmaceuticals","slug":"tarsus-pharmaceuticals","ticker":"TARS","exchange":"NASDAQ","domain":"tarsusrx.com","description":"Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreem","hq":"Irvine, CA","founded":0,"employees":"370","ceo":"","sector":"Ophthalmology / Eye Care","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":65.18,"stockChange":0.52,"stockChangePercent":0.8,"marketCap":"$2.8B","metrics":{"revenue":535079008,"revenueGrowth":106.9,"grossMargin":80,"rdSpend":0,"netIncome":-48265000,"cash":388732000,"dividendYield":0,"peRatio":22.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Lotilaner ophthalmic solution, 0.25%","genericName":"Lotilaner ophthalmic solution, 0.25%","slug":"lotilaner-ophthalmic-solution-0-25","indication":"Demodex blepharitis","status":"marketed"},{"name":"TP-03 Vehicle","genericName":"TP-03 Vehicle","slug":"tp-03-vehicle","indication":"Ocular surface disease (specific indication under investigation in Phase 3)","status":"phase_3"},{"name":"TP-03, 0.25%","genericName":"TP-03, 0.25%","slug":"tp-03-0-25","indication":"Other","status":"phase_2"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TP-03","genericName":"TP-03","slug":"tp-03","indication":"Dry eye disease","status":"phase_3"}]}],"pipeline":[{"name":"TP-03","genericName":"TP-03","slug":"tp-03","phase":"phase_3","mechanism":"TP-03 is a monoclonal antibody targeting the CD40 receptor.","indications":["Dry eye disease"],"catalyst":""},{"name":"Lotilaner ophthalmic solution, 0.25%","genericName":"Lotilaner ophthalmic solution, 0.25%","slug":"lotilaner-ophthalmic-solution-0-25","phase":"marketed","mechanism":"Lotilaner is a non-selective sigma receptor antagonist that reduces ocular surface inflammation and irritation associated with Demodex mites.","indications":["Demodex blepharitis","Ocular rosacea"],"catalyst":""},{"name":"TP-03 Vehicle","genericName":"TP-03 Vehicle","slug":"tp-03-vehicle","phase":"phase_3","mechanism":"TP-03 Vehicle is a topical ophthalmic formulation designed to deliver active pharmaceutical ingredients to the ocular surface.","indications":["Ocular surface disease (specific indication under investigation in Phase 3)"],"catalyst":""},{"name":"TP-03, 0.25%","genericName":"TP-03, 0.25%","slug":"tp-03-0-25","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"marketed":1,"phase_2":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":451360000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":451360000},{"period":"2024-12-31","value":182953000},{"period":"2023-12-31","value":17447000},{"period":"2022-12-31","value":25816000}],"grossProfit":420676000,"grossProfitHistory":[{"period":"2025-12-31","value":420676000},{"period":"2024-12-31","value":170127000},{"period":"2023-12-31","value":15854000},{"period":"2022-12-31","value":24861000}],"rdSpend":64322000,"rdSpendHistory":[{"period":"2025-12-31","value":64322000},{"period":"2024-12-31","value":53386000},{"period":"2023-12-31","value":50312000},{"period":"2022-12-31","value":42624000}],"sgaSpend":427323000,"operatingIncome":-70969000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-70969000},{"period":"2024-12-31","value":-120569000},{"period":"2023-12-31","value":-143158000},{"period":"2022-12-31","value":-62712000}],"netIncome":-66418000,"netIncomeHistory":[{"period":"2025-12-31","value":-66418000},{"period":"2024-12-31","value":-115554000},{"period":"2023-12-31","value":-135893000},{"period":"2022-12-31","value":-62091000}],"eps":-1.59,"epsHistory":[{"period":"2025-12-31","value":-1.59},{"period":"2024-12-31","value":-3.07},{"period":"2023-12-31","value":-4.62},{"period":"2022-12-31","value":-2.52}],"cash":183641000,"cashHistory":[{"period":"2025-12-31","value":183641000},{"period":"2024-12-31","value":94819000},{"period":"2023-12-31","value":224947000},{"period":"2022-12-31","value":71660000}],"totalAssets":562158000,"totalLiabilities":218732000,"totalDebt":72438000,"equity":343426000,"operatingCashflow":-12451000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-12451000},{"period":"2024-12-31","value":-83027000},{"period":"2023-12-31","value":-117493000},{"period":"2022-12-31","value":-49030000}],"capex":-9859000,"capexHistory":[{"period":"2025-12-31","value":-9859000},{"period":"2024-12-31","value":-6567000},{"period":"2023-12-31","value":-5502000},{"period":"2022-12-31","value":-506000}],"freeCashflow":-22310000,"dividendsPaid":null,"buybacks":null,"employees":370,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":130682000,"ebit":-4256000,"ebitda":-3813000,"period":"2025-12-31","revenue":151668000,"epsBasic":-0.2,"netIncome":-8373000,"rdExpense":18035000,"epsDiluted":-0.2,"grossProfit":140741000,"operatingIncome":-7976000},{"sga":108633000,"ebit":-10469000,"ebitda":-10009000,"period":"2025-09-30","revenue":118697000,"epsBasic":-0.3,"netIncome":-12585000,"rdExpense":16284000,"epsDiluted":-0.3,"grossProfit":110388000,"operatingIncome":-14529000},{"sga":103013000,"ebit":-18246000,"ebitda":-17793000,"period":"2025-06-30","revenue":102660000,"epsBasic":-0.48,"netIncome":-20340000,"rdExpense":15594000,"epsDiluted":-0.48,"grossProfit":96423000,"operatingIncome":-22184000},{"sga":84995000,"ebit":-23046000,"ebitda":-22586000,"period":"2025-03-31","revenue":78335000,"epsBasic":-0.64,"netIncome":-25120000,"rdExpense":14409000,"epsDiluted":-0.64,"grossProfit":73124000,"operatingIncome":-26280000},{"sga":69030000,"ebit":-20939000,"ebitda":-20507000,"period":"2024-12-31","revenue":66408000,"epsBasic":-0.6,"netIncome":-23113000,"rdExpense":16873000,"epsDiluted":-0.6,"grossProfit":61482000,"operatingIncome":-24421000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":65.18,"previousClose":64.66,"fiftyTwoWeekHigh":85.25,"fiftyTwoWeekLow":38.51,"fiftyTwoWeekRange":"38.51 - 85.25","fiftyDayAverage":67.22,"twoHundredDayAverage":66.94,"beta":0.53,"enterpriseValue":2481873152,"forwardPE":22.6,"priceToBook":8.08,"priceToSales":5.24,"enterpriseToRevenue":4.64,"enterpriseToEbitda":-50.63,"pegRatio":0,"ebitda":-49018000,"ebitdaMargin":-9.2,"freeCashflow":-21268124,"operatingCashflow":-16452000,"totalDebt":88676000,"debtToEquity":25.4,"currentRatio":3.74,"returnOnAssets":-5.9,"returnOnEquity":-14,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":94.22,"targetHighPrice":100,"targetLowPrice":88,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.1,"institutionHeldPercent":104,"sharesOutstanding":43023959,"floatShares":32724453,"sharesShort":4817273,"shortRatio":9.38,"shortPercentOfFloat":11.2,"epsTrailing":-1.11,"epsForward":2.89,"revenuePerShare":12.54,"bookValue":8.07,"officers":[{"age":null,"name":"Dr. Bobak R. Azamian M.D.","title":"Co-Founder, President, CEO & Chairman"},{"age":63,"name":"Mr. Jeffrey S.  Farrow CPA","title":"CFO & Chief Strategy Officer"},{"age":57,"name":"Dr. Seshadri  Neervannan Ph.D.","title":"Chief Operating Officer"},{"age":47,"name":"Dr. Bryan  Wahl J.D., M.D.","title":"General Counsel & Corporate Secretary"},{"age":47,"name":"Mr. Aziz  Mottiwala M.B.A.","title":"Chief Commercial Officer"},{"age":null,"name":"Mr. David  Nakasone","title":"Head of Investor Relations"},{"age":null,"name":"Ms. Adrienne  Kemp","title":"Senior Director of Corporate Communications"},{"age":47,"name":"Mr. Matthew  Rossen M.B.A.","title":"Vice President of Marketing"}],"industry":"Biotechnology","irWebsite":"","website":"https://tarsusrx.com","phone":"949 418 1801"}}